Chronic diseases such as cancer, cardiovascular diseases, and diabetes are major health challenges globally, leading to a growing demand for innovative treatments. For instance, as per the Centers for Disease Control and Prevention (CDC), six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes.
Similarly, as per the WHO estimates, cardiovascular diseases account nearly 17.9 million deaths annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million including kidney disease deaths caused by diabetes).
Cell signaling plays a crucial role in the development and progression of these diseases, making it a key focus for research and drug development.
Thus, as our understanding of cell signaling pathways deepens, new therapeutic targets are being identified, leading to the development of novel drugs and therapies. This, in turn, is driving the growth of the market as pharmaceutical companies and research institutions invest in this field to address the rising burden of chronic diseases.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The global cell signaling market was valued at USD 4.4 billion in 2023 and is anticipated to grow at 6.3% CAGR between 2024 – 2032, owing to the increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders.
The consumables segment in the market accounted for USD 2.6 billion in 2023, driven by the continuous development of new consumables with enhanced sensitivity and specificity.
North America cell signaling market is anticipated to reach USD 3.7 billion by 2032, attributed to a well-established healthcare infrastructure, robust R&D activities, and high healthcare expenditure.
Becton, Dickinson and Company, Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., Danaher Corporation, Merck KGaA, PerkinElmer Inc., Promega Corporation, QIAGEN N.V. and Thermo Fisher Scientific, Inc.